Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database

Acta Diabetologica
Jean-Luc FaillieFrench Pharmacovigilance Centers Network

Abstract

In the recent past, concerns have raised regarding the potential risk of acute pancreatitis among type 2 diabetic patients using incretin-based drugs such as glucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase 4 (DPP-4) inhibitors. The aim of this study is to investigate the association between exposure to incretin-based drugs and the occurrence of pancreatitis reported in the French Pharmacovigilance Database. The case/non-case method was performed from serious adverse drug reactions (ADRs) involving antihyperglycemic agents (except insulin alone) reported to the French pharmacovigilance system between March 2008 (first marketing of an incretin-based drug in France) and March 2013. Cases were defined as reports of pancreatitis, and all other serious ADRs were considered non-cases. Disproportionality was assessed by calculating reporting odds ratios (ROR) adjusted for age, gender, history of pancreatitis, other antihyperglycemic drugs and other drugs associated with a higher risk of pancreatitis. Among 3,109 serious ADRs, 147 (4.7 %) reports of pancreatitis were identified as cases and 2,962 reports (95.3 %) of other ADRs as non-cases. Among the cases, 122 (83.0 %) involved incretin-based drugs. Disproportionality ...Continue Reading

References

Jul 12, 2002·Statistics in Medicine·Peter G M van der HeijdenJacques W van der Hofstede
Nov 5, 2003·Gastroenterology·UNKNOWN American Gastroenterological Association Clinical Practice Committee
Jan 30, 2004·British Journal of Clinical Pharmacology·Andrew M WilsonAnne Holbrook
Aug 23, 2005·Expert Opinion on Drug Safety·Manfred HaubenEugene P Van Puijenbroek
Sep 27, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Manfred HaubenLester Reich
May 13, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Lorna Hazell, Saad A W Shakir
Sep 18, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Antoine ParienteNicholas Moore
May 30, 2008·European Journal of Clinical Pharmacology·A SommetUNKNOWN French Network of Regional Pharmacovigilance Centres
Sep 2, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Anil R Balani, James H Grendell
Apr 10, 2009·Pharmacoepidemiology and Drug Safety·A Bate, S J W Evans
Sep 14, 2010·Diabetes Care·Antonio Gonzalez-PerezLuis A García Rodríguez
Feb 16, 2011·Diabetes, Obesity & Metabolism·D D DoreJ D Seeger
Feb 22, 2011·Gastroenterology·Michael ElashoffPeter C Butler
Apr 13, 2011·BMJ : British Medical Journal·Nigel Hawkes
Jun 11, 2011·British Journal of Clinical Pharmacology·Jean-Louis MontastrucMaryse Lapeyre-Mestre
Mar 16, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·M WentenG L Bloomgren
Aug 1, 2012·Diabetes Technology & Therapeutics·John A RomleyAnne L Peters
Sep 27, 2012·Diabetes Research and Clinical Practice·Carlos AlvesAna F Macedo
Apr 25, 2013·BMJ : British Medical Journal·Deborah Cohen
May 24, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Samuel S EngelBarry J Goldstein
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators

❮ Previous
Next ❯

Citations

Apr 26, 2014·BMJ : British Medical Journal·Jean-Luc FaillieSamy Suissa
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Theodosios D FilippatosMoses S Elisaf
Jan 30, 2015·Expert Opinion on Drug Safety·André J Scheen
Oct 16, 2015·International Journal of Cardiology·Liberata SportielloAnnalisa Capuano
Dec 19, 2018·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·Noe Quesada-Vázquez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.